Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.
Aged
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Colonic Neoplasms
/ drug therapy
Drug Interactions
Extracellular Signal-Regulated MAP Kinases
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immunoglobulins, Intravenous
/ administration & dosage
Male
Middle Aged
Oxaliplatin
/ pharmacology
Xenograft Model Antitumor Assays
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
10
07
2020
accepted:
05
01
2021
revised:
04
12
2020
pubmed:
10
2
2021
medline:
23
9
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
Recent evidence proves that intravenous human immunoglobulin G (IgG) can impair cancer cell viability. However, no study evaluated whether IgG application benefits cancer patients receiving chemotherapeutics. Influence of pharmaceutical-grade human IgG on the viability of a series of patient-derived colon cancer cell lines with and without chemotherapeutic intervention was determined. Cell death was analysed flow cytometrically. In addition, the influence of oxaliplatin and IgG on the ERK1/2-signalling pathway was evaluated by western blots. We evaluated the effects of pharmaceutical IgG, such as PRIVIGEN The present study demonstrates that pharmaceutical IgG, such as PRIVIGEN
Sections du résumé
BACKGROUND
Recent evidence proves that intravenous human immunoglobulin G (IgG) can impair cancer cell viability. However, no study evaluated whether IgG application benefits cancer patients receiving chemotherapeutics.
METHODS
Influence of pharmaceutical-grade human IgG on the viability of a series of patient-derived colon cancer cell lines with and without chemotherapeutic intervention was determined. Cell death was analysed flow cytometrically. In addition, the influence of oxaliplatin and IgG on the ERK1/2-signalling pathway was evaluated by western blots.
RESULTS
We evaluated the effects of pharmaceutical IgG, such as PRIVIGEN
CONCLUSIONS
The present study demonstrates that pharmaceutical IgG, such as PRIVIGEN
Identifiants
pubmed: 33558709
doi: 10.1038/s41416-021-01272-6
pii: 10.1038/s41416-021-01272-6
pmc: PMC8039037
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Oxaliplatin
04ZR38536J
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1411-1420Références
Tashiro, T., Kawada, Y., Sakurai, Y. & Kidani, Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed. Pharmacother. 43, 251–260 (1989).
pubmed: 2790145
doi: 10.1016/0753-3322(89)90004-8
Raymond, E., Chaney, S. G., Taamma, A. & Cvitkovic, E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 9, 1053–1071 (1998).
pubmed: 9834817
doi: 10.1023/A:1008213732429
Schmoll, H. J. & Cassidy, J. Integrating oxaliplatin into the management of colorectal cancer. Oncologist 6, 24–28 (2001).
pubmed: 11585971
doi: 10.1634/theoncologist.6-suppl_4-24
Alcindor, T. & Beauger, N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr. Oncol. 18, 18–25 (2011).
pubmed: 21331278
pmcid: 3031353
doi: 10.3747/co.v18i1.708
Raymond, E., Buquet-Fagot, C., Djelloul, S., Mester, J., Cvitkovic, E., Allain, P. et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 8, 876–885 (1997).
pubmed: 9402315
doi: 10.1097/00001813-199710000-00009
Yothers, G., O’Connell, M. J., Allegra, C. J., Kuebler, J. P., Colangelo, L. H., Petrelli, N. J. et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J. Clin. Oncol. 29, 3768–3774 (2011).
pubmed: 21859995
pmcid: 3188282
doi: 10.1200/JCO.2011.36.4539
Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med 350, 2343–2351 (2004).
pubmed: 15175436
doi: 10.1056/NEJMoa032709
Barton, M. K. Oxaliplatin in the adjuvant treatment of colon cancer. CA Cancer J. Clin. 62, 3–4 (2012).
pubmed: 22095255
doi: 10.3322/caac.21131
Brenner, H., Kloor, M. & Pox, C. P. Colorectal cancer. Lancet 383, 1490–1502 (2014).
pubmed: 24225001
doi: 10.1016/S0140-6736(13)61649-9
Youn, C. K., Kim, M. H., Cho, H. J., Kim, H. B., Chang, I. Y., Chung, M. H. et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res. 64, 4849–4857 (2004).
pubmed: 15256455
doi: 10.1158/0008-5472.CAN-04-0348
Santoro, V., Jia, R., Thompson, H., Nijhuis, A., Jeffery, R., Kiakos, K. et al. Role of reactive oxygen species in the abrogation of oxaliplatin activity by cetuximab in colorectal cancer. J. Natl. Cancer Inst. 108, djv394 (2016).
pubmed: 26719345
doi: 10.1093/jnci/djv394
Schweyer, S., Soruri, A., Meschter, O., Heintze, A., Zschunke, F., Miosge, N. et al. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br. J. Cancer 91, 589–598 (2004).
pubmed: 15266324
pmcid: 2409982
doi: 10.1038/sj.bjc.6601919
Singh, S., Upadhyay, A. K., Ajay, A. K. & Bhat, M. K. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. FEBS Lett. 581, 289–295 (2007).
pubmed: 17208232
doi: 10.1016/j.febslet.2006.12.035
Wang, X., Martindale, J. L. & Holbrook, N. J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275, 39435–39443 (2000).
pubmed: 10993883
doi: 10.1074/jbc.M004583200
Sheridan, C., Brumatti, G., Elgendy, M., Brunet, M. & Martin, S. J. An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 29, 6428–6441 (2010).
pubmed: 20802529
doi: 10.1038/onc.2010.380
Sapir, T., Blank, M. & Shoenfeld, Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann. N. Y Acad. Sci. 1051, 743–778 (2005).
pubmed: 16127014
doi: 10.1196/annals.1361.118
Rayburn, E. R., Ezell, S. J. & Zhang, R. Anti-inflammatory agents for cancer therapy. Mol. Cell Pharm. 1, 29–43 (2009).
doi: 10.4255/mcpharmacol.09.05
Carr, C., Ng, J. & Wigmore, T. The side effects of chemotherapeutic agents. Curr. Anaesth. Crit. Care 19, 70–79 (2008).
doi: 10.1016/j.cacc.2008.01.004
Shoenfeld, Y. & Fishman, P. Gamma-globulin inhibits tumor spread in mice. Int Immunol. 11, 1247–1252 (1999).
pubmed: 10421782
doi: 10.1093/intimm/11.8.1247
Merimsky, O., Meller, I., Inbar, M., Bar-Yehuda, S., Shoenfeld, Y. & Fishman, P. A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int J. Oncol. 20, 839–843 (2002).
pubmed: 11894134
Fishman, P., Bar-Yehuda, S. & Shoenfeld, Y. IVIg to prevent tumor metastases (Review). Int J. Oncol. 21, 875–880 (2002).
pubmed: 12239629
Sherer, Y., Levy, Y. & Shoenfeld, Y. IVIG in autoimmunity and cancer-efficacy versus safety. Expert Opin. Drug Saf. 1, 153–158 (2002).
pubmed: 12904149
doi: 10.1517/14740338.1.2.153
Leibovitz, A., Stinson, J. C., McCombs, W. B., McCoy, C. E., Mazur, K. C. & Mabry, N. D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36, 4562–4569 (1976).
pubmed: 1000501
Capes-Davis, A., Theodosopoulos, G., Atkin, I., Drexler, H. G., Kohara, A., MacLeod, R. A. et al. Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J. Cancer 127, 1–8 (2010).
pubmed: 20143388
doi: 10.1002/ijc.25242
Hughes, P., Marshall, D., Reid, Y., Parkes, H. & Gelber, C. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? Biotechniques 43, 575 (2007). 577-578, 581-572 passim.
pubmed: 18072586
doi: 10.2144/000112598
Mullins, C. S., Micheel, B., Matschos, S., Leuchter, M., Bürtin, F., Krohn, M. et al. Integrated biobanking and tumor model establishment of human colorectal carcinoma provides excellent tools for preclinical research. Cancers (Basel) 11, E1520 (2019). pii.
doi: 10.3390/cancers11101520
van Dongen, J. J. M., Langerak, A. W., Brüggemann, M., Evans, P. A. S., Hummel, M., Lavender, F. L. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257–2317 (2003).
pubmed: 14671650
doi: 10.1038/sj.leu.2403202
McLain, L. & Dimmock, N. J. A human CD4+ T-cell line expresses functional CD64 (Fc gamma RI), CD32 (Fc gamma RII), and CD16 (Fc gamma RIII) receptors but these do not enhance the infectivity of HIV-1-IgG complexes. Immunology 90, 109–114 (1997).
pubmed: 9038720
pmcid: 1456708
doi: 10.1046/j.1365-2567.1997.00116.x
Zhang, X., Kumstel, S., Jiang, K., Meng, S., Gong, P., Vollmar, B. et al. LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer. J. Adv. Res. 20, 9–21 (2019).
pubmed: 31193017
pmcid: 6514270
doi: 10.1016/j.jare.2019.04.006
Danieli, M. G., Gelardi, C., Pedini, V. & Gabrielli, A. Potential anti-tumor activity of intravenous and subcutaneous immunoglobulin. Isr. Med Assoc. J. 20, 782–783 (2018).
pubmed: 30550011
Carmi, Y., Spitzer, M. H., Linde, I. L., Burt, B. M., Prestwood, T. R., Perlman, N. et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 521, 99–104 (2015).
pubmed: 25924063
pmcid: 4877172
doi: 10.1038/nature14424
Marin, J. J., Sanchez de Medina, F., Castano, B., Bujanda, L., Romero, M. R., Martinez-Augustin, O. et al. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab. Rev. 44, 148–172 (2012).
pubmed: 22497631
doi: 10.3109/03602532.2011.638303
Alimbetov, D., Askarova, S., Umbayev, B., Davis, T. & Kipling, D. Pharmacological targeting of cell cycle, apoptotic and cell adhesion signaling pathways implicated in chemoresistance of cancer cells. Int J. Mol. Sci. 19, 1690 (2018).
pmcid: 6032165
doi: 10.3390/ijms19061690
Liao, Q., Liu, W., Liu, Y., Wang, F., Wang, C., Zhang, J. et al. Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis. Oncotarget 6, 40081–40094 (2015).
pubmed: 26472025
pmcid: 4741881
doi: 10.18632/oncotarget.5542
Qiu, X., Zhu, X., Zhang, L., Mao, Y., Zhang, J., Hao, P. et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res. 63, 6488–6495 (2003).
pubmed: 14559841
Geng, Z. H., Ye, C. X., Huang, Y., Jiang, H. P., Ye, Y. J., Wang, S. et al. Human colorectal cancer cells frequently express IgG and display unique Ig repertoire. World J. Gastrointest. Oncol. 11, 195–207 (2019).
pubmed: 30918593
pmcid: 6425329
doi: 10.4251/wjgo.v11.i3.195
Niu, N., Zhang, J., Huang, T., Sun, Y., Chen, Z., Yi, W. et al. IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLoS ONE 7, e47362 (2012).
pubmed: 23133595
pmcid: 3486799
doi: 10.1371/journal.pone.0047362
Phipps, A. I., Limburg, P. J., Baron, J. A., Burnett-Hartman, A. N., Weisenberger, D. J., Laird, P. W. et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 148, 77–87 (2015).
pubmed: 25280443
doi: 10.1053/j.gastro.2014.09.038
Okita, A., Takahashi, S., Ouchi, K., Inoue, M., Watanabe, M., Endo, M. et al. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget 9, 18698–18711 (2018).
pubmed: 29721154
pmcid: 5922348
doi: 10.18632/oncotarget.24617
Sadanandam, A., Wang, X., de Sousa E Melo, F., Gray, J. W., Vermeulen, L., Hanahan, D. et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle 13, 353–357 (2014).
pubmed: 24406433
pmcid: 3956531
doi: 10.4161/cc.27769
Gossage, L. & Madhusudan, S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat. Rev. 33, 565–577 (2007).
pubmed: 17707593
doi: 10.1016/j.ctrv.2007.07.001
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y. P., Uetake, H., Danenberg, K. D. et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19, 4298–4304 (2001).
pubmed: 11731512
doi: 10.1200/JCO.2001.19.23.4298
Ley, R., Balmanno, K., Hadfield, K., Weston, C. & Cook, S. J. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J. Biol. Chem. 278, 18811–18816 (2003).
pubmed: 12646560
doi: 10.1074/jbc.M301010200
Sheridan, C., Brumatti, G. & Martin, S. J. Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J. Biol. Chem. 283, 22128–22135 (2008).
pubmed: 18508762
doi: 10.1074/jbc.M800271200
Allen, L. F., Sebolt-Leopold, J. & Meyer, M. B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. 30, 105–116 (2003).
pubmed: 14613031
doi: 10.1053/j.seminoncol.2003.08.012